IMMX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 55.90%

Insider Buying (Last 12 Months): $341,415.00

Insider Selling (Last 12 Months): $0.00

Immix Biopharma Insider Trading History Chart

Immix Biopharma Share Price & Price History

^$1.47

▼ -0.0941 (-6.03%)

As of 09/30/2024 04:13 PM ET

Days: 30 | 90 | 365

From Porter & Company | Ad

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.

Immix Biopharma Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/16/2024	Carey Ng	Director	Buy	10,000	$1.86	$18,600.00	20,000
7/24/2024	Jason Hsu	Director	Buy	6,000	$2.15	$12,900.00	822,200
7/18/2024	Jason Hsu	Director	Buy	3,200	$2.07	$6,624.00	816,200
6/7/2024	Gabriel S Morris	CFO	Buy	2,500	$2.12	$5,300.00	285,834
6/7/2024	Ilya M Rachman	CEO	Buy	2,600	$2.13	$5,538.00	1,136,259
6/4/2024	Gabriel S Morris	CFO	Buy	3,300	$1.81	$5,973.00	283,334
5/14/2024	Gabriel S Morris	CFO	Buy	4,500	$2.23	$10,035.00	85,816
5/14/2024	Ilya M Rachman	CEO	Buy	4,300	$2.25	$9,675.00	912,000
12/11/2023	Jason Hsu	Director	Buy	31,000	$4.67	$144,770.00	813,000
12/8/2023	Jason Hsu	Director	Buy	25,000	$4.88	$122,000.00	782,000
9/14/2023	Carey Ng	Director	Buy	10,000	$2.58	$25,800.00	10,000
9/12/2023	Helen C Adams	Director	Buy	13,000	$2.96	$38,480.00	13,000
9/7/2023	Melissa Jane Buchan	Director	Buy	20,000	$2.46	$49,200.00	20,000
9/5/2023	Magda Marquet	Director	Buy	10,000	$2.47	$24,700.00	11,000
8/31/2023	Magda Marquet	Director	Buy	1,000	$2.01	$2,010.00	1,000
11/14/2022	Ilya M Rachman	CEO	Buy	5,200	$1.00	$5,200.00	907,700
7/14/2022	Sean Senn	Major Shareholder	Sell	200	$2.75	$550.00	899,800

$2 Trillion Disappears Because of Fed's Secretive New Move

From Stansberry Research | Ad

$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.

Click here to see his new research now.

SEC Filings (Institutional Ownership Changes) for Immix Biopharma (NASDAQ:IMMX)

11.26% of Immix Biopharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Immix Biopharma Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/16/2024	Invst LLC	27,000	$57K	0.0%	N/A	0.102%
8/12/2024	XTX Topco Ltd	17,663	$35K	0.0%	-66.2%	0.067%
8/9/2024	Renaissance Technologies LLC	154,685	$0.31M	0.0%	-41.7%	0.586%
8/7/2024	AIGH Capital Management LLC	1,406,680	$2.79M	0.9%	-9.5%	5.326%
5/10/2024	Tocqueville Asset Management L.P.	37,800	$0.12M	0.0%	+89.0%	0.143%
4/26/2024	Tritonpoint Wealth LLC	24,526	$75K	0.0%	N/A	0.093%
2/7/2024	Jump Financial LLC	18,500	$0.13M	0.0%	N/A	0.093%
2/6/2024	Private Advisor Group LLC	99,775	$0.69M	0.0%	N/A	0.502%
2/1/2024	OLD National Bancorp IN	10,000	$69K	0.0%	N/A	0.050%
1/30/2024	Imprint Wealth LLC	34,483	$0.24M	0.2%	+49.4%	0.174%
11/9/2023	Tocqueville Asset Management L.P.	12,000	$41K	0.0%	N/A	0.061%
10/23/2023	Commonwealth Equity Services LLC	28,855	$99K	0.0%	+26.4%	0.147%
7/28/2023	Koshinski Asset Management Inc.	51,001	$0.14M	0.0%	N/A	0.339%
7/25/2023	UMB Bank n.a.	72,639	$0.20M	0.0%	-26.8%	0.483%
4/11/2023	UMB Bank n.a.	99,300	$0.18M	0.0%	N/A	0.714%
2/10/2023	Murchinson Ltd.	67,200	$0.15M	0.0%	N/A	0.482%
2/7/2023	Lynwood Capital Management Inc.	25,000	$58K	0.1%	N/A	0.179%
2/1/2023	Bank of Montreal Can	15,000	$36K	0.0%	N/A	0.108%
5/11/2022	InterOcean Capital Group LLC	15,900	$38K	0.0%	N/A	0.115%
2/14/2022	Altium Capital Management LP	122,388	$0.44M	0.1%	N/A	1.616%
2/14/2022	Murchinson Ltd.	695,600	$2.48M	0.2%	N/A	9.183%
2/9/2022	Context Capital Management LLC	11,532	$41K	0.0%	N/A	0.152%
2/2/2022	PVG Asset Management Corp	20,000	$71K	0.3%	N/A	0.264%
2/1/2022	Eidelman Virant Capital	29,856	$0.10M	0.0%	N/A	0.394%

Data available starting January 2016

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Today's Range

Now: $1.47

$1.43

$1.56

50 Day Range

MA: $1.99

$1.56

$2.28

52 Week Range

Now: $1.47

$1.43

$7.75

Volume

146,332 shs

Average Volume

186,917 shs

Market Capitalization

$38.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.17

Who are the company insiders with the largest holdings of Immix Biopharma?: Immix Biopharma's top insider investors include:
Ilya M Rachman (CEO)
Jason Hsu (Director)
Gabriel S Morris (CFO)
Carey Ng (Director)
Melissa Jane Buchan (Director)
Helen C Adams (Director)
Magda Marquet (Director)
Learn More about top insider investors at Immix Biopharma.